Merck
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85
Dividends
As of March 13, 2026, the global financial landscape is navigating a delicate transition. Following the aggressive rate hikes of previous years and a subsequent "soft landing" throughout 2025, the U.S. economy is currently operating in a lower-gear growth phase. In this environment, investors have pivoted away
Merck
Merck & Co., Inc. (NYSE: MRK) has reached a pivotal milestone in the HIV treatment landscape, announcing successful Phase 3 results for its once-daily oral regimen combining doravirine and islatravir (DOR/ISL). The data, presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026), confirms that the two-drug
ASCO GU 2026
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that could redefine the standard of care in bladder and kidney cancers. With the conference just ten days away, the
Moderna
In a landmark moment for the future of personalized medicine, Moderna, Inc. (NASDAQ: MRNA) and Merck & Co., Inc. (NYSE: MRK) announced groundbreaking five-year follow-up data on January 20, 2026, for their experimental mRNA cancer vaccine. The results, stemming from the Phase 2b KEYNOTE-942 trial, demonstrated that the combination of
Merck
As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic masterstrokes. While many of its "Big Pharma" peers have spent the last 24 months mired in
Pharmaceutical
Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s (IRA) negotiation provisions. This milestone represents a fundamental shift in the federal government’s role
Dogs of the Dow
As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a simpler, time-tested strategy for the new year. The "Dogs of the Dow" strategy, which involves purchasing the